TLR7 and neoplasm: In animal models, the combination of IRE with a checkpoint inhibition and TLR7 agonist, not only improved the local effects of IRE but also generated therapeutic abscopal effects against small secondary tumours, modelling the potential eradication of distant micrometastatic disease [40].